GMP Analysis for Biopol Chemicals
Generated: 2026-02-07T18:46:29.097184
================================================================================

STRUCTURED DATA:
  GMP Price: ₹0
  GMP %: None%
  Issue Price: ₹None
  Expected Listing: ₹None
  IPO Status: None

================================================================================

COMPREHENSIVE ANALYSIS:
**Comprehensive GMP Analysis for Biopol Chemicals IPO**

### 1. Current GMP Status

- **Current GMP Price and Percentage**: The current GMP (Grey Market Premium) for Biopol Chemicals IPO is ₹- (nil), indicating no premium or discount in the grey market as of the latest available data.
- **Issue Price and Expected Listing Price**: The issue price band is fixed at ₹102 to ₹108 per share. With a nil GMP, the expected listing price could be around the issue price, assuming no significant changes in market sentiment.
- **GMP Indicator**: The neutral GMP suggests that the market is not showing a strong preference for the IPO at the moment, which could be due to various factors including the SME nature of the IPO and the current market conditions.

### 2. Market Sentiment Analysis

- **Market Demand**: The nil GMP indicates a balanced or neutral market demand for the Biopol Chemicals IPO. It suggests that the market is neither overly enthusiastic nor pessimistic about the issue.
- **Subscription Status**: As of the first day, the IPO had seen an overall subscription of nearly 40%, with the retail portion booked at 36%, and the segment reserved for NIIs subscribed to 4%. This indicates a moderate level of interest but does not necessarily reflect the final subscription status.
- **Investor Confidence**: The investor confidence appears to be cautious, given the SME nature of the IPO and the current market conditions. The lack of a significant premium in the grey market may indicate that investors are adopting a wait-and-watch approach.

### 3. Listing Gain Potential

- **Expected Listing Gains**: Based on the current GMP, the expected listing gains are minimal or nil, suggesting that investors may not see significant immediate returns upon listing.
- **Risk-Reward Assessment**: The risk-reward assessment for this IPO seems balanced, with the potential for moderate gains if the company performs well post-listing. However, the SME segment can be volatile, and investors should be prepared for potential fluctuations.
- **Comparison with Similar IPOs**: There is no direct comparison provided in the context, but generally, SME IPOs can be more volatile than mainboard IPOs.

### 4. IPO Timeline & Status

- **Current IPO Status**: The Biopol Chemicals IPO opened for public subscription on February 6, 2026, and is scheduled to close on February 10, 2026.
- **Important Dates**: Key dates include the IPO opening and closing dates (February 6 to February 10, 2026), the basis of allotment (February 11, 2026), refunds (February 12, 2026), credit to demat accounts (February 12, 2026), and the expected listing date (February 13, 2026).
- **Time-Sensitive Insights**: Investors should keep an eye on the subscription numbers and any changes in the GMP as the IPO progresses, as these can provide insights into the market's perception of the issue.

### 5. Investment Recommendation

- **Should Investors Apply?**: The decision to apply for this IPO should be based on a thorough analysis of the company's financials, growth prospects, and the industry's potential. Given the neutral GMP and moderate subscription, investors may consider applying if they believe in the company's long-term potential.
- **Grey Market Trends**: The grey market trends are currently neutral, which may indicate a lack of strong speculative interest in the IPO.
- **Risk Factors**: Investors should consider the risks associated with SME IPOs, including higher volatility and the potential for significant price movements post-listing.

### 6. Key Takeaways

- **Neutral GMP**: The current GMP is nil, indicating a balanced market sentiment.
- **Moderate Subscription**: The IPO has seen a moderate level of subscription, which may indicate cautious investor interest.
- **SME Volatility**: Investors should be aware of the potential volatility associated with SME IPOs.
- **Long-Term Potential**: The decision to invest should consider the company's long-term growth prospects and industry potential.
- **Market Watch**: Keeping an eye on the subscription numbers and any changes in the GMP can provide valuable insights for investment decisions.

In conclusion, the Biopol Chemicals IPO presents a neutral scenario in terms of market sentiment, with a nil GMP and moderate subscription levels. Investors should approach this IPO with caution, considering both the potential for long-term growth and the risks associated with SME listings.

================================================================================
Sources: 3 websites scraped
  1. https://ipowatch.in/biopol-chemicals-ipo-gmp-grey-market-premium/
  2. https://www.livemint.com/market/ipo/biopol-chemicals-ipo-day-1-gmp-subscription-status-price-other-key-details-of-sme-ipo-in-10-points-11770358373752.html
  3. https://firstock.in/blog/fractal-analytics-ipo-gmp-2026/
